[{"address1": "National Innovation Centre", "address2": "Suite 212a 2 4 Cornwallis Street Eveleigh", "city": "Sydney", "state": "NSW", "zip": "2015", "country": "Australia", "phone": "61 2 9209 4037", "fax": "61 2 9209 4037", "website": "https://www.claritypharmaceuticals.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States. The company's products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. It develops theranostic therapy and imaging products for the treatment of cancer in children and adults. The company was incorporated in 2010 and is based in Sydney, Australia.", "fullTimeEmployees": 50, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan John Taylor Ph.D.", "title": "Executive Chairman", "fiscalYear": 2023, "totalPay": 535199, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David K. Green BEc., CA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 150198, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Colin David Biggin Ph.D.", "title": "COO & Non-Independent Executive Director", "fiscalYear": 2023, "totalPay": 429105, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Parker", "title": "CEO, MD & Executive Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Harris BSc., M.B.A., Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "totalPay": 123437, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Sadetskaya", "title": "Director of Corporate Communications.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mary  Bennett", "title": "Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shaemus  Gleason", "title": "Executive Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Othon  Gervasio", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Eva  Lengyelova", "title": "Executive Vice President of Clinical Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 10, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 2.56, "dayLow": 2.56, "dayHigh": 2.56, "regularMarketOpen": 2.56, "regularMarketDayLow": 2.56, "regularMarketDayHigh": 2.56, "beta": 1.641, "volume": 1600, "regularMarketVolume": 1600, "averageVolume": 3968, "averageVolume10days": 1740, "averageDailyVolume10Day": 1740, "bid": 2.04, "ask": 2.2, "bidSize": 40000, "askSize": 40000, "marketCap": 669744256, "fiftyTwoWeekLow": 2.036, "fiftyTwoWeekHigh": 6.398, "priceToSalesTrailing12Months": 58.2049, "fiftyDayAverage": 2.72038, "twoHundredDayAverage": 4.000381, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 498005376, "floatShares": 218329766, "sharesOutstanding": 321327008, "heldPercentInsiders": 0.27889, "heldPercentInstitutions": 0.12644, "impliedSharesOutstanding": 328951008, "bookValue": 0.469, "priceToBook": 4.341151, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -42324428, "trailingEps": -0.1, "enterpriseToRevenue": 43.28, "enterpriseToEbitda": -11.154, "52WeekChange": -0.5434978, "SandP52WeekChange": 0.22894537, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CLRPF", "underlyingSymbol": "CLRPF", "shortName": "Clarity Pharmaceuticals Ltd.", "longName": "Clarity Pharmaceuticals Ltd", "firstTradeDateEpochUtc": 1723728600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e3adc917-5183-3806-b4b8-3bebee6c5494", "messageBoardId": "finmb_263530964", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.036, "recommendationKey": "none", "totalCash": 136505664, "totalCashPerShare": 0.438, "ebitda": -44647592, "quickRatio": 18.438, "currentRatio": 19.046, "totalRevenue": 11506665, "revenuePerShare": 0.042, "returnOnAssets": -0.24188, "returnOnEquity": -0.39285, "grossProfits": 11506665, "freeCashflow": -29524536, "operatingCashflow": -43237104, "revenueGrowth": 0.497, "grossMargins": 1.0, "operatingMargins": -4.36944, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]